HealthcareServices

Chemotherapy-Induced Nausea and Vomiting (CINV) Market 2026–2030: Forecasting Business Opportunities Ahead

February 23, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the chemotherapy-induced nausea and vomiting (cinv) market from 2026–2035 with trusted insights from The Business Research Company

What size range is anticipated for the Chemotherapy-Induced Nausea and Vomiting (CINV) Market from 2026 to 2030?

The chemotherapy-induced nausea and vomiting (cinv) market size has seen substantial growth in recent years. It is anticipated to expand from $3.13 billion in 2025 to $3.35 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.0%. The expansion observed historically can be ascribed to factors such as the increasing utilization of highly emetogenic chemotherapy, a growing understanding of treatment-related side effects, the emergence of advanced antiemetic drugs, the broadening of oncology treatment initiatives, and improvements in clinical guidelines for cinv management.

The market for chemotherapy-induced nausea and vomiting (cinv) is projected to experience robust expansion in the coming years. This market is anticipated to reach $4.57 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 8.0%. Factors driving this growth during the forecast period include a surging demand for innovative antiemetics, the increasing embrace of tailored antiemetic treatments, the broadening of outpatient chemotherapy provisions, an intensified emphasis on adherence to prescribed treatment regimens, and improvements in sustained-release drug formulations. Key trends projected for the forecast period encompass a greater uptake of combined antiemetic approaches, an increased reliance on extended-release CINV medications, a heightened focus on care models centered around patients, the development of more extensive preventive CINV management guidelines, and a stronger accent on improving patients’ quality of life.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13031&type=smp

What Drivers Are Affecting Demand In The Chemotherapy-Induced Nausea and Vomiting (CINV) Market?

The rising incidence of cancer is projected to fuel the expansion of the chemotherapy-induced nausea and vomiting (CINV) market in the future. Cancer occurs when certain cells in the body multiply without control and disseminate to different parts of the body. With the ongoing increase in cancer diagnoses, there’s an amplified motivation to create more potent and specific anti-emetic therapies to mitigate CINV, a troubling consequence of chemotherapy. This intensified attention on managing CINV has resulted in progress in deciphering its fundamental processes and devising new treatments. For instance, in January 2023, the American Cancer Society (ACS), a US-based volunteer health organization committed to cancer eradication, projected that the United States would experience 1.9 million new cancer cases (approximately 5,370 cases per day) and 609,820 cancer deaths (about 1,670 deaths per day) during 2023. Consequently, the growing occurrence of cancer will propel the chemotherapy-induced nausea and vomiting (CINV) market.

Which Segments Are Gaining Traction In The Chemotherapy-Induced Nausea and Vomiting (CINV) Market?

The chemotherapy-induced nausea and vomiting (cinv) market covered in this report is segmented –

1) By Form: Injectables, Oral, Transdermal Patches

2) By Drug Class: 5-HT3 Receptor Antagonists, Neurokinin-1 Receptor Antagonists, Corticosteroids, Cannabinoids, Other Drug Classes

3) By Emetogenic Risk: Highly Emetogenic Chemotherapy (HEC), Moderately Emetogenic Chemotherapy (MEC), Low Emetogenic Chemotherapy (LEC)

4) By Distribution Channel: CINV Hospitals, Cancer Research Institute, Retail Pharmacies, Online Pharmacies, Drug Stores

5) By Application: Gynecology, Urology, Gastrointestinal Surgery, Other Applications

Subsegments:

1) By Injectables: Intravenous (IV) Solutions, Intramuscular (IM) Injections

2) By Oral: Tablets, Capsules, Liquid Formulations

3) By Transdermal Patches: Fentanyl Patches, Scopolamine Patches

What Industry Trends Are Transforming The Chemotherapy-Induced Nausea and Vomiting (CINV) Market?

Leading companies in the chemotherapy-induced nausea and vomiting (CINV) market are pursuing novel product developments, such as fixed intravenous antiemetics, to gain a competitive edge. This form of antiemetic involves a predefined drug dose administered intravenously to prevent or alleviate nausea and vomiting, commonly employed in chemotherapy or post-surgical recovery. For instance, in January 2023, Glenmark Pharmaceuticals Limited, an India-based manufacturer of pharmaceuticals, generics, and over-the-counter products, introduced AKYNZEO I.V. in India. This product stands as the first fixed intravenous antiemetic combination specifically designed to prevent chemotherapy-induced nausea and vomiting (CINV). It brings together netupitant and palonosetron to tackle both immediate and prolonged phases of nausea and vomiting. The product provides the convenience of a single dose, better complete response rates, and an improved quality of life for cancer patients. Clinical research demonstrates its particular efficacy for patients undergoing highly emetogenic chemotherapy.

Who Are The Prominent Global Companies Shaping The Chemotherapy-Induced Nausea and Vomiting (CINV) Market Landscape?

Major companies operating in the chemotherapy-induced nausea and vomiting (cinv) market are Pfizer Inc., Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Novartis AG, AstraZeneca plc, GlaxoSmithKline plc, Baxter International Inc., Teva Pharmaceuticals Industries Ltd., Bausch Health Companies Inc., Eisai Co. Ltd., Jazz Pharmaceuticals plc, Ono Pharmaceutical Co. Ltd., Dr. Reddy’s Laboratories Ltd., Kyowa Kirin Inc., Amneal Pharmaceuticals Inc., Mundipharma International Limited, Insys Therapeutics Inc., Lupin Limited, Helsinn Holding S.A., Heron Therapeutics Inc., Camurus AB, Cadila Pharmaceuticals Limited, Acacia Pharma Ltd., Soligenix Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/chemotherapy-induced-nausea-and-vomiting-cinv-global-market-report

Which Region Currently Holds The Largest Share Of The Chemotherapy-Induced Nausea and Vomiting (CINV) Market?

North America was the largest region in the chemotherapy-induced nausea and vomiting (CINV) market in 2025. The regions covered in the chemotherapy-induced nausea and vomiting (cinv) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Chemotherapy-Induced Nausea and Vomiting (CINV) Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=13031&type=smp

Browse Through More Reports Similar to the Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market 2026, By The Business Research Company

Chemotherapy Induced Peripheral Neuropathy Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/chemotherapy-induced-peripheral-neuropathy-treatment-global-market-report

Chemotherapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/chemotherapy-global-market-report

Chemotherapy Induced Anemia Market Report 2026

https://www.thebusinessresearchcompany.com/report/chemotherapy-induced-anemia-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795